伊立替康节拍式化疗联合索拉非尼对人肝癌细胞HepG2及内皮细胞HUVECs的抑制作用

Effects of metronomic irinotecan chemotherpy combined with Sorafenib on human hepatocellular carcinoma strain HepG2 and human umbilical vascular endothelial cells HUVECs

关键词:  HepG2细胞  人脐静脉内皮细胞  索拉非尼  伊立替康  节拍式化疗

Key words:  [Key words]　hepatic carcinoma strain HepG2  human umbilical vascular endothelial cells  Sorafenib  irinotecan  metronomic chemotherapy

摘要:

[摘要]　目的　观察伊立替康（CPT-11）节拍式化疗联合索拉非尼(Sorafenib)对人肝癌细胞HepG2生长的影响及对血管内皮细胞的抑制作用。　方法　取对数生长的HepG2细胞、人脐静脉内皮细胞（HUVECs）培养后分组给药：（1）对照组，加培养液。（2）索拉非尼组，6 μmol/L。（3）CPT-11（LDM）组，CPT-11 30 μg/mL。（4）CPT-11（TDM）组，CPT-11 160 μg/mL。（5）CPT-11（LDM）30 μg/mL +索拉非尼 6 μmol/L组。用MTT法检测各实验组人HepG2细胞及HUVECs细胞培养24 h、48 h、72 h后的平均OD值，计算抑制率。　结果　CPT-11（LDM）组对HepG2细胞抑制作用不明显，明显低于其他实验组（P<0.05）。 CPT-11（LDM）与索拉非尼联合用药对HUVECs细胞的抑制作用最明显，显著高于单独用药（P<0.05）。　结论　小剂量伊立替康（CPT-11）体外能够抑制内皮细胞增殖，但对肿瘤细胞HepG2抑制作用有限。靶向治疗联合节拍式化疗效果更佳。

Abstract:

[Abstract] Objective To observe the inhibition effect of low dose CPT-11 combined with Sorafenib on the growth of human heptatic carcinoma strain HepG2 and the proliferation of human umbilical vascular endothelial cells (HUVECs). Methods HUVECs and HepG2 cells were divided into 5 groups: control group, Sorafenib-treated group 6 μmol/L, CPT-11(LDM)- treated group 30 μg/mL, CPT-11(TDM)- treated group 160 μg/mL and Sorafenib+ CPT-11(LDM)-treated group. The cell proliferation inhibition rate was calculated with MTT assays. Results Both Sorafenib and Low dose CPT-11 can inhibit the proliferation of HUVECs, and the inhibition rate in group sorafenib+CPT-11(LDM) treated group higher than that in sorafenib group and CPT-11(LDM) group (P<0.05). LDM chemotherapy had little inhibition effect on HepG2. The inhibition rate to HepG2 in CPT-11(LDM) group was significantly lower than that in others group (P<0.05). Conclusion The anti-tumour effects of Low-dose CPT-11 could be from its angiogenesis inhibition. The combination of Sorafenib and CPT-11(LDM) would be a better choice.